EMA Authorised: Eporatio (epoetin theta) — Ratiopharm GmbH

View source ↗

Summary

Authorised status for Eporatio (epoetin theta) by Ratiopharm GmbH for treatment areas including chronic kidney failure, anemia, and cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Chronic Kidney Disease

Drugs mentioned

• Eporatio (epoetin theta)

Snippet

Status: Authorised. Therapeutic area: Kidney Failure, Chronic;Anemia;Cancer. MAH: Ratiopharm GmbH. Decision date: 26/09/2023